ASCO 2022 | Cellular therapies and their place in the CLL treatment landscape
Kerry Rogers
• 3 Jun 2022
Kerry Rogers, MD, The Ohio State University, Columbus, OH, shares some insights into the role of cellular therapies in the future treatment of chronic lymphocytic leukemia (CLL). Although there are no FDA-approved CAR-T therapies for the treatment of CLL, Dr Rogers highlights the importance of clinical trials investigating these cellular therapies and the promising outcomes of these trials. Dr Rogers then explains how CAR-T will play an important role when treating patients who no longer benefit from other targeted therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
